[Clinico-immunologic changes in patients with cervical cancer after treatment with thymalin].
Dekster. L I LI; Nikolaeva. L Ia LIa; Bokhman. Ia V IaV; Letskiĭ. V B VB; Morozov. V G VG
Key Findings
- Thymalin administration was associated with improved immune markers in cervical cancer patients.
- Patients receiving thymalin showed a beneficial effect in various immunosuppressive states linked to the cancer.
- The study suggests thymalin could be incorporated into multi‑modal cancer therapy regimens.
Practical Outcomes
- For biohackers, thymalin appears to have immune‑enhancing properties, but evidence is limited to a cancer patient cohort. It may be worth monitoring for broader immune support, yet no clear dosing or safety data for healthy individuals are provided. Use with caution and consider waiting for more robust, non‑cancer studies before adding it to personal protocols.
Summary
A small clinical trial gave the peptide thymalin to 50 women with cervical cancer and found it helped boost their immune system. The researchers think adding thymalin to cancer treatment plans could be useful because it seemed to improve immune function in these patients.
Abstract
The results of a clinical study of a polypeptide preparation of the thymus-thymalin in 50 patients with cervical carcinoma are discussed. Thymalin was found to exert a beneficial effect in various immuno-suppressive states involved in carcinoma of uterine cervix. Since the preparation has a distinct stimulating effect, its administration should be included into different schemes of complex therapy of cervical carcinoma.
Study Information
pubmed
1984